<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">THALIDOMIDE </span><br/>(tha-lid'o-mide)<br/><span class="topboxtradename">Thalomid<br/></span><b>Classifications:</b> <span class="classification">immunomodulator</span>; <span class="classification">tumor necrosis factor modifier</span><br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Mechanism of action in inducing immunosuppression is unknown, however, drug has several antiinflammatory and immunologic actions.
         Antiinflammatory effects may be due to its inhibition of neutrophil chemotaxis and decrease of monocyte phagocytosis. Immunosuppressive
         effect may result from suppression of excessive tumor necrosis factor-alpha (TNF-alpha) production. Also, reduces helper T
         cells and increases suppressor T cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antiinflammatory and immunosuppressive actions. Indicated by control of cutaneous manifestations of erythema nodosum leprosum.</p>
<h1><a name="uses">Uses</a></h1>
<p>Acute and maintenance treatment of cutaneous manifestations of moderate to severe erythema nodosum leprosum. Refractory Crohn's
         disease.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Stimulate appetite in patients with HIV-associated cachexia, lupus, multiple myeloma.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to thalidomide; peripheral neuropathy. Pregnancy (category X), lactation, children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Liver and kidney disease; CHF or hypertension; constipation or other GI disorders; neurologic disorders or history of neuritis.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Erythema Nodosum Leprosum</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 100300 mg q.d. (max: 400 mg/d) times at least 2 wk<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>1117 y,</i> 100 mg q.d.<br/><br/><span class="indicationtitle">Refractory Crohn's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50100 mg q.d. (doses up to 300 mg studied)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at bedtime and at least 1 h after the evening meal.</li>
<li>Give this drug only to persons who understand and have signed the required consent form.</li>
<li>Verify, prior to administration, that this drug was prescribed and dispensed only by persons registered by the STEPS (System
            for Thalidomide Education and Prescribing Safety) program.
         </li>
<li>Store at 15°30° C (59°86° F); protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, back pain, chills, facial edema, <span class="speceff-common">fever,</span> malaise, pain. <span class="typehead">CNS:</span> Drowsiness, <span class="speceff-common">somnolence,</span> peripheral neuropathy (possibly irreversible), <span class="speceff-common">dizziness,</span> orthostatic hypotension, headache, agitation, insomnia, nervousness, paresthesia, tremor, vertigo, seizures. <span class="typehead">CV:</span> Bradycardia, peripheral edema, hyperlipidemia. <span class="typehead">GI:</span> Abdominal pain, anorexia, constipation, <span class="speceff-common">diarrhea,</span> dry mouth, flatulence, abnormal liver function tests, nausea, oral moniliasis. <span class="typehead">Hematologic:</span> Neutropenia, anemia, <span class="speceff-common">leukopenia,</span> lymphadenopathy. <span class="typehead">Respiratory:</span> Pharyngitis, rhinitis, sinusitis. <span class="typehead">Skin:</span>
<span class="speceff-common">Rash,</span> acne, nail disorder, fungal dermatitis, pruritus, sweating, <span class="speceff-life">toxic epiderma necrolysis</span>. <span class="typehead">Body as a Whole:</span> Hypersensitivity reaction (rash, fever, tachycardia, hypotension), HIV viral load increase, infection. <span class="typehead">Urogenital:</span> Teratogenicity, albuminuria, hematuria, impotence. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Enhances sedation associated with <span class="classification">barbiturates</span>, <b>alcohol,</b>
<b>chlorpromazine,</b>
<b>reserpine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly absorbed from GI tract. <span class="typehead">Peak:</span> 2.95.7 h. <span class="typehead">Distribution:</span> Crosses placenta; present in ejaculate in males. <span class="typehead">Metabolism:</span> Does not appear to be hepatically metabolized. <span class="typehead">Half-Life:</span> 67.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor WBC with differential prior to therapy and periodically thereafter.</li>
<li>Monitor carefully for and immediately report S&amp;S of peripheral neuropathy. Discontinue drug and notify prescriber if peripheral
            neuropathy is suspected.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not share this medication with anyone else under any circumstances.</li>
<li>Use effective methods of birth control (both women and men); starting 1 mo before, during, and 1 mo following discontinuation
            of thalidomide therapy. Men <small>
<b>must</b>
</small> use condoms when engaging in sexual activity.
         </li>
<li>Exercise caution while driving or engaging in potentially hazardous activities because drug may cause dizziness.</li>
<li>Report pain, numbness, or tingling in the hands or feet to physician immediately.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>